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relationshipAbstract The main purpose of this study is to synthesize novel heterocyclic derivatives of fatty
acids which are also biologically important. The simple, efﬁcient and one-pot synthesis of two novel
series of 1-long chain alkanoyl/alkenoyl/hydroxyalkenoyl-3-methyl-1H-pyrazol-5(4H)-ones 2(a–e)
and 2-long chain alkenoyl/hydroxyalkenoyl-3H-phthalazin-1,4-diones 3(b–e) is achieved by the
reaction of ethylacetoacetate/phthalic anhydride and long chain alkyl/alkenyl/hydroxyalkenyl
hydrazides 1(a–e). Although some methods are available for the synthesis of phthalazindiones
and pyrazolones, the development of a new synthetic method for the efﬁcacious build up of hetero-
cycles (phthalazindiones and pyrazolones) substituted with long alkanoyl/alkenoyl/hydroxyalke-
noyl chain is an interesting challenge in the ﬁeld of synthesis of novel compounds of fatty acids
that includes heterocyclization and derivatization of fatty acids. Compounds 2(a–e) were synthe-
sized by the cyclization reaction between ethylacetoacetate and long alkyl/alkenyl/hydroxyalkenyl
chain hydrazides 1(a–e). Compounds 3(b–e) were synthesized by the reaction of phthalic anhydride
and long alkenyl/hydroxyalkenyl chain hydrazides 1(b–e) in absolute ethanol/glacial AcOH. Struc-
tures of all the newly synthesized compounds have been elucidated by means of IR, 1H NMR, 13C
NMR and MS. Newly synthesized compounds were evaluated for in vitro antibacterial and anti-
fungal activities and their structure–activity relationship studies have been carried out.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
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Nowadays, human beings are totally dependent on the medi-
cines derived from heterocyclic rings. In many pharmaceuti-
cally active compounds heterocyclic rings are found, because
both heterocycles and medicines are interrelated. The phthal-
azine nucleus also has very marked pharmacological and bio-
logical applications due to its antitumour (Loh et al., 2005),
antihypertensive (Demirayak et al., 2004), antithrombotic
(Johnsen et al., 2003), antidiabetic (Lenz et al., 2002) and anti-
inﬂammatory (Dogruer et al., 2004) activities. Pyrazole ring
represents an interesting template for medicinal and combina-
torial chemistry (Pevarello et al., 2006) because they play a key
role in biologically active compounds. Indeed, several pyrazole
derivatives have been reported to possess antimicrobial (Vije-
sha et al., 2011), antiviral (Narule, 2011), antiandrogenic
(Amr et al., 2006), analgesic (Parashar et al., 2010), antiinﬂam-
matory (Dohutia et al., 2013), antidiabetic (Das et al., 2008)
and antioxidant (Mohan and Ananthan, 2011) properties. Pyr-
azole and pyrazolone derivatives were also reported to possess
antiinﬂammatory, postmenopausal, osteoporosis, antagonists,NN
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Figure 1 Structurally related dranticoagulants and angiotensin activities (Lee et al., 2003). In
drug molecules such as celecoxib (a) (Singh et al., 2004), pyra-
zofurine (b) (Do¨mling and Ugi, 2000) and many others, the
pyrazole ring is the key moiety. Literature survey also reveals
that (Z)-4-(4-hydroxy-3-methoxy benzylidene)-1-(3-nitro-
phenyl)-3-phenyl-1H-pyrazol-5(4H)-one (c) (a pyrazolone
derivative) was found to be a non-steroidal Farnesoid X
Receptor (FXR) selective antagonist (Huang et al., 2012; Ma
et al., 2010). Azelastine (d) is a potent, second-generation,
selective histamine antagonist (histamine-H1-receptor antago-
nist) and it is a member of the phthalazinone family, it shows
relevant bronchodilatory activity used for treatment of asthma
(McTavish and Sorkin, 1989) and has also been reported to
induce vasorelaxation in vitro assays (Lee et al., 1990). Com-
mercially available drug, hydralazine (e), is one of the ﬁrst
antihypertensive drugs developed in 1950s and due to its vaso-
dilator action it is considered as lead for introducing new
drugs. Hydralazine belongs to phthalazine drug family and
directly acts as a smooth muscle relaxant used to treat
hypertension by acting as a vasodilator in arteries and arteri-
oles. A slight change in the structure of hydralazine led to
the discovery of some phthalazine derivatives which wereO
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292 A. Ahmad et al.found to possess antiparasitic, antifungal, antimicrobial, anti-
psychotic, antineoplastic activities (Olmo et al., 2006). The well
known HAV 3C inhibitor (f) is also a phthalazindione deriva-
tive which has been found to possess inhibitory properties
against hepatitis A virus 3C proteinase (Jain and Vederas,
2004). Pyrazolo[1,2-b]phthalazine-dione derivatives were
reported as antiinﬂammatory, analgesic, antihypoxic and
antipyretic agents (Al’-Assar et al., 2002). Our investigations
show that the structure of some drugs which are mainly based
on pyrazole, pyrazolone, phthalazine and phthalazinone,
phthalazindione nuclei (Fig. 1) is closely related to the
structure of the target compounds i.e., 1,3-disubstituted-1H-
pyrazol-5(4H)-one and 2-substituted-3H-1,4-phthalazindione
fatty acid analogues.
Carboxylic acids having long alkyl/alkenyl/hydroxyalkenyl
chains are found to be pharmacologically active antimicrobial
agents (Rauf and Parveen, 2005) and these are also useful in
the treatment of renal, cardiovascular and hepatic disorders
(Greetings et al., 2003). Also, some fatty acid derivatives have
been found to possess antitumor activity and antidepressant
activity (Khan et al., 2011; Jubie et al., 2012). Vital utility
range of pyrazolones and phthalazindiones, fascinating
properties of fatty acids and in continuation of our work in
derivatization and heterocyclization of selected fatty acids
(Farshori et al., 2010, 2011a,b; Varshney et al., 2013) enthused
us to design a simple, efﬁcacious and one-pot synthetic route
for the synthesis of two novel series of 1,3-disubstituted-1H-
pyrazol-5(4H)-one and 2-substituted-3H-1,4-phthalazindioneRCONHNH2
1(a-e)
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O
R C
O
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Scheme 1 Synthesis of 1,3-disubstituted-1H-pyrazol-5(4fatty acid analogues using selected long alkyl/alkenyl/hydrox-
yalkenyl chain hydrazides as starting materials. Furthermore,
this synthetic methodology involves the use of cheap and
readily available solvents and commercially available reagents,
giving the desired products in good to excellent yields. The
ambidexterity of this synthetic route makes it applicable for
library synthesis in drug discovery effects.
2. Materials and methods
2.1. Physical and spectroscopic measurements
(9Z, 12R)-12-Hydroxyoctadec-9-enoic and (9R, 12Z)-
9-hydroxyoctadec-12-enoic acids were isolated from Ricinus
communis and Wrightia tinctoria seed oils respectively follow-
ing Gunstone’s partition (Gunstone, 1954). Undec-10-enoic
acid (Purity 98%), (Z)-octadec-9-enoic acid (97%) and palmat-
ic acid were purchased from Fluka Chemicals (Buck Switzer-
land). Ethylacetoacetate and phthalic anhydride were
purchased from Merck, Mumbai, India. Thin layer chroma-
tography (TLC) was done on glass plated with a layer of silica
gel G (Merck, Mumbai, India 0.5 mm thickness). Column
chromatography was carried out on silica gel (Merck, Mum-
bai, India, 60–120 mesh). IR spectra were recorded on Shima-
dzu 8201 PC spectrometer and absorption given in cm1. 1H
NMR and 13C NMR were recorded in CDCl3 on a Bruker
DRX-400 instrument. The chemical shifts (d) were measuredNH
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H)-ones and 2-substituted-3H-1,4-phthalazindiones.
Table 1 Structure and physicochemical parameters of all newly synthesized compounds.
Code Compound Molecular
formula
Molecular
weight
Physical
state
M.P. % Yield
2a
NN
O
C
O
CH3
11CH2
C20H36O2N2 336.44 Colorless
oily
– 75
2b
NN
O
C
O
CH3
3
HZ
HE
CH2
C15H24O2N2 264.32 Colorless
oily
– 74
2c
NN
O
C
O
CH3
5 5 CH2
C22H38O2N2 362.48 Reddish
brown oily
– 70
2d
NN
O
C
O
CH3
OH
3 5
CH2
C22H38O3N2 378.48 Reddish
brown oily
– 71
2e
NN
O
C
O
CH3OH
2 5
CH2
C22H38O3N2 378.48 Reddish
brown oily
– 73
3b
HN
N
O
O
C
O3
HZ
HE
CH2
C19H24O3N2 328.36 White
powder
85–87 85
3c
HN
N
O
O
C
O
5 5 CH2
C26H38O3N2 426.52 White
powder
91–92 82
3d
HN
N
O
O
C
O
OH
3 5
CH2
C26H38O4N2 442.52 White
powder
70–72 70
3e
HN
N
O
O
C
O
OH
2 5
CH2
C26H38O4N2 442.52 White
powder
74–76 74
*M.P.: Melting point.
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294 A. Ahmad et al.relative to TMS as an internal standard and quoted in ppm.
Coupling constants (J) are expressed in Hertz (Hz). The mass
spectra were recorded on JEOL-SX 102/DA-600 mass
spectrometer.
2.1.1. General procedure for the preparation of 1,3-disubstituted-
1H-pyrazol-5(4H)-ones 2(a-e)
Fatty acid hydrazides 1(a–e) previously synthesized in our lab-
oratory (Rauf et al., 2007) were used as the starting material. A
mixture of 0.01 mol of fatty acid hydrazides 1(a–e) and 0.1 mol
(13 mL) of ethylacetoacetate was heated on parafﬁn bath.
After sometime the reaction mixture turned into a reddish oily
syrup. The reaction was continued till all the reactants were
consumed. After completion of the reaction, the reaction mix-
ture was cooled and worked up with dichloromethane and
water. The product was puriﬁed by column chromatography.
All the products were oily in nature and were elucidated on
the basis of their spectral data.
2.1.2. General procedure for the preparation of 2-substituted-
3H-1,4-phthalazinediones 3(b-e)
0.1 mole of fatty acid hydrazides 1(b–e) and 0.1 mol of phthalic
anhydride in ethanol (5 mL) were taken in a round bottom
ﬂask and 0.005 mol of glacial acetic acid was added. Reaction
mixture was reﬂuxed for 10–12 h, and then poured into
crushed ice, a solid product was precipitated. All the products
were in the form of white powder and were elucidated on the
basis of their spectral data. The reaction sequences leading
to the formation of these two novel series of compounds are
outlined in Scheme 1 and physiochemical parameters of all
the newly synthesized compounds are tabulated in the Table 1.
2.2. Biological activity
2.2.1. Antibacterial studies
A stock solution of 1 mg/mL was prepared by dissolving all
the newly synthesized compounds in DMSO. Filter paper disc
method (FPDM) (Bauer et al., 1966) was used for testing the
antibacterial activity of all the target compounds and standard
doxycycline Media with DMSO was set up as control. On
nutrient agar all cultures were systematically maintained and
incubated overnight at 37 C. At 1000 rpm the culture was cen-
trifuged, pellets were resuspended and then diluted in sterile
normal saline solution (NSS) to obtain viable 105 cfu/mL.
On nutrient agar plates approximately 0.1 mL of diluted bac-
terial culture suspension was spread uniformly with the help
of spreader. Sterile 8 mm discs (Hi-media Pvt. Ltd) were
impregnated with the test compounds. Antibiotic disc, doxycy-
cline (30 lg/disc Hi-Media) was used as control. The disc was
placed on the nutrient agar plate. Each plate had one control
disc impregnated with the solvent. The plates were then incu-
bated for 24 h at 37 C, and the resulting zones of inhibition
were measured (mm).
2.2.2. Antifungal studies
The synthesized compounds were dissolved in DMSO. Media
with DMSO was set up as control. All cultures were consis-
tently maintained on SDA (sabouraud’s dextrose agar) and
incubated at 28 C. Spore formation of ﬁlamentous fungiwas prepared from 7 day old culture in sterile normal
saline solution (8% NaCl) and approximately diluted to obtain
105cfu/mL. The inoculums of non-sporing fungi, Candida albi-
cans were performed by growing the culture in SD (sabou-
raud’s) broth at 37 C for overnight. At 1000 rpm the culture
was centrifuged, pellets were resuspended and then diluted in
sterile normal saline solution (NSS) to obtain viable 105 cfu/
mL. On SDA plates approximately 0.1 mL of diluted fungal
culture suspension was spread uniformly with the help of
spreader. Sterile 8 mm discs (Hi-media Pvt. Ltd) were impreg-
nated with the test compounds. Antibiotic disc, nystatin
(30 lg/disc Hi-Media) was used as control. The disc was placed
onto the SDA plate. Each plate had one control disc impreg-
nated with the solvent. The plates were incubated at 28 C
for ﬁlamentous fungi for 72 h or more, while for C. albicans
plates were incubated at 37 C for 18–48 h. Antifungal activity
was determined by measuring the diameters of the inhibition
zone (mm).3. Results and discussion
3.1. Chemistry
The present study is based on the synthesis and characteriza-
tion of two novel series of pyrazolone and phthalazindione
derivatives of long chain fatty acids. The fatty acid hydrazides
1(a–e) were used as the starting material and they were pre-
pared from the fatty acids following previously reported meth-
od (Rauf et al., 2007). The derivatives of 1,3-disubstituted-1H-
pyrazol-5(4H)-ones 2(a–e) were synthesized by the condensa-
tion of long chain alkyl, alkenyl (internal and terminal) and
hydroxyalkenyl carboxylic acid hydrazides 1(a–e) with ethy-
lacetoacetate, followed by cyclization. The synthesized com-
pounds were identiﬁed on the basis of IR, 1H NMR, 13C
NMR and MS. The structure of compound 2b was conﬁrmed
by the appearance of an absorption band at 1603 cm1 due to
C‚N stretch. Another absorption band for C‚O was ob-
served at 1698 cm1. The absorption band at 2932 cm1 was
observed for aliphatic stretch. The 1H NMR spectrum was
more informative in assigning the structure. In addition to
peaks of fatty acid chain, the singlet at d4.18 for two protons
of pyrazolone ring CH2 was observed along with a singlet at
d1.57 for CH3 protons which is directly attached to the ring.
In 13C NMR, peaks at d178.6, d130.2, d50.8 were observed.
Further evidence was obtained by recording mass spectrum.
The mass spectrum showed characteristic molecular ion peak
which was in accordance with the molecular formula. Similar
type of spectral data were obtained for compounds 2a, 2c, 2d
and 2e.
Similarly, the other novel series of 2-substituted-3H-1,4-
phthalazindione derivatives 3(b–e) were synthesized by the
condensation of long chain alkenyl (internal and terminal)
and hydroxyalkenyl carboxylic acid hydrazides 1(b–e) with
phthalic anhydride in ethanol and catalytic amount of glacial
acetic acid was used. Products were in the form of white pow-
der. All the newly synthesized compounds were characterized
on the basis of IR, 1H NMR, 13C NMR and MS. Compound
3b showed IR absorption bands at 3228 cm1 for N-H stretch,
at 2925 cm1 for C-H stretch and at 1599 cm1 for C‚O
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to the N–H proton. Also a multiplet at d7.74–7.89 was ob-
served for four aromatic protons. In 13C NMR, peaks at
d171.8, d165.3, d139.2, d134.7, d130.9, d129.1, d128.4, and
d127.1 were observed. The mass spectrum showed a character-
istic molecular ion peak which was in accordance with the
molecular formula. Similar type of spectral data were obtained
for compounds 3c, 3d and 3e.
3.1.1. The spectroscopic and analytical data for the synthesized
compounds 2(a–e) and 3(b–e) are presented below
3.1.1.1. 1-(Hexadecanoyl)-3-methyl-1H-pyrazol-5(4H)-one
(2a). IR (KBr, cm1): 2920 (C–H stretching), 1680 (C‚O
stretching), 1592 (C‚N stretching). 1H NMR (CDCl3, dH):
4.12 (2H, s, CH2 ring), 2.25 (2H, t, J= 7.59 Hz, CH2CO),
1.95 (2H, m, CH2CH2CO), 1.56 (3H, s, CH3 ring), 1.22
(24H, br.s, (CH2)12 chain), 0.85 (3H, dist.t, CH3).
13C NMR
(CDCl3, dC): 176.9, 165.4, 127.9, 45.8, 35.6, 33.8, 33.7, 32.9,
31.8, 31.2, 30.0, 29.9, 29.8, 29.7, 27.4, 27.0, 25.4, 23.8, 22.8,
14.0. MS (ESI): m/z= 359.500 found [M+ Na]+, calculated
[M+ Na]+ = 401.470.
3.1.1.2. 1-(Undec-100-enoyl)-3-methyl-1H-pyrazol-5(4H)-one
(2b). IR (KBr, cm1): 2932 (C-H stretching), 1698 (C‚O
stretching), 1603 (C‚N stretching). 1H NMR (CDCl3, dH):
5.82 (1H, tdd, JH9CH2 ¼ 6:50HZ , JHHZ ¼ 10:30HZ , JHHE=17.10
HZ, CH2 = CH), 5.01 (1H, dd, JHZH ¼ 10:30HZ,
JHZHE ¼ 2:00HZ, HZC= CH), 4.91 (1H, dd,
JHEH ¼ 16:90HZ, JHEHZ ¼ 2:00HZ, HEC= CH), 4.18
(2H, s, CH2 ring), 2.51 (2H, t, J= 7.38 Hz, CH2CO), 2.06
(2H, m, CH2 = CH-CH2), 1.71 (2H, m, CH2CH2CO), 1.57
(3H, s, CH3), 1.25 (10H, br.s, CH2(CH2)5).
13C NMR (CDCl3,
dC): 178.6, 174.0, 130.2, 130.0, 129.9, 50.8, 34.4, 33.9, 31.9,
30.8, 30.1, 29.7, 27.1, 24.2, 18.0. MS (ESI): m/z= 287.121
found [M+ Na]+, calculated [M+Na]+ = 287.310.
3.1.1.3. 1-[(90Z) (Octadec-90-enoyl)]-3-methyl-1H-pyrazol-
5(4H)-one (2c). IR (KBr, cm1): 2924 (C-H stretching),
1700 stretching, 1598 (C = N stretching). 1H NMR (CDCl3,
dH): 5.35 (2H, m, CH=CH), 4.20 (2H, s, CH2 ring), 2.36
(2H, t, J= 7.52 HZ, CH2CO), 2.24 (4H, m,
CH2CH= CHCH2), 2.00 (2H, m, CH2CH2CO), 1.61 (3H, s,
CH3), 1.25 (20H, br.s, (CH2)10), 0.88 (3H, dist.t, CH3).
13C
NMR (CDCl3, dC): 180.1, 165.8, 127.2, 123.1, 122.9, 48.1,
35.0, 33.1, 31.9, 29.7, 29.6, 29.4, 29.3, 29.2, 29.1, 27.1, 25.3,
25.0, 24.7, 15.4, 14.1. MS (ESI) m/z= 385.381 found
[M+ Na]+, calculated [M+ Na]+ = 385.471.
3.1.1.4. 1-[(90Z, 120R)-120-Hydroxy-octadec-90-enoyl]-3-
methyl-1H-pyrazol-5(4H)-one (2d). IR (KBr, cm1): 3400
(O-H stretching), 2929 (C–H stretching), 1685 (C = O stretch-
ing), 1579 (C = N stretching). 1H NMR (CDCl3, dH): 5.34
(2H, m, CH=CH), 4.87 (1H, m, CHOH), 4.11 (2H, s, CH2
ring), 2.27 (2H, t, J= 7.47 HZ, CH2CO), 2.21 (1H, m,
CHOH), 1.96 (4H, m, CH2CH= CHCH2), 1.85 (2H, m,
CH2CH2CO), 1.55 (3H, s, CH3 ring), 1.21 (18H, br.s,
(CH2)9), 0.80 (3H, dist.t, CH3).
13C NMR (CDCl3, dC):
182.9, 173.9, 133.2, 132.8, 123.8, 72.0, 50.1, 37.4, 36.7, 34.3,
31.9, 31.7, 30.1, 29.6, 29.5, 29.1, 28.9, 27.3, 25.6, 24.9, 15.9,
14.1. MS (ESI) m/z= 401.299 found [M+ Na]+, calculated
[M+ Na]+ = 401.470.3.1.1.5. 1-[(90R, 120Z)-90-Hydroxy-octadec-120enoyl]-3-
methyl-1H-pyrazol-5(4H)-one (2e). IR (KBr, cm1): 3391
(O-H stretching), 2933 (C–H stretching), 1680 (C = O stretch-
ing), 1570 (C = N stretching). 1H NMR (CDCl3, dH): 5.35
(2H, m, CH=CH), 4.86 (1H, m, CHOH), 4.13 (2H, s, CH2
ring), 2.25 (2H, t, J= 7.50 HZ, CH2CO), 2.19 (1H, m,
CHOH), 1.95 (4H, m, CH2CH= CHCH2), 1.86 (2H, m,
CH2CH2CO), 1.53 (3H, s, CH3 ring), 1.23 (18H, br.s,
(CH2)9), 0.82 (3H, dist.t, CH3).
13C NMR (CDCl3, dC):
181.9, 176.9, 133.1, 132.5, 123.0, 72.9, 50.4, 38.4, 37.7, 33.3,
31.8, 31.7, 30.2, 29.5, 29.2, 29.0, 28.6, 27.1, 25.7, 24.6, 15.9,
14.3. MS (ESI) m/z= 401.302 found [M+Na]+, calculated
[M+Na]+ = 401.470.
3.1.1.6. 2-(Undec-100-enoyl)-3H-1,4-phthalazindione (3b). IR
(KBr, cm1): 3228 (N-H stretching), 2925 (C–H stretching),
1599 (C = O stretching). 1H NMR (CDCl3, dH): 8.01 (1H, s,
NH), 7.74–7.89 (4H, m, ArH), 5.80 (1H, tdd, JH9CH2=6.71
HZ, JHHZ=10.90 HZ, JHHE=16.82 HZ, CH2 = CH), 5.01
(1H, dd, JHZH=10.11 HZ, JHZHE=2.20 HZ, HZC= CH),
4.93 (1H, dd, JHEH=17.45 HZ, JHEHZ=2.20 HZ,
HEC= CH), 2.39 (2H, t, J= 7.50 Hz, CH2CO), 2.03 (2H,
m, CH2 = CH–CH2), 1.70 (2H, m, CH2CH2CO), 1.28 (10H,
br.s, CH2(CH2)5).
13C NMR (CDCl3, dC): 175.1, 171.8,
165.3, 139.2, 134.7, 130.9, 129.1, 128.4, 127.1, 124.0, 114.1,
33.9, 33.8, 29.3, 29.2, 29.0, 28.9, ‘‘one signal hidden’’, 25.1.
MS (ESI): m/z= 351.333 found [M+Na]+, calculated
[M+Na]+ = 351.353.
3.1.1.7. 2-[(Z)-Octadec-90-enoyl]-3H-1,4-phthalazidione (3c).
IR (KBr, cm1): 3232 (N-H stretching), 2922 (C–H stretching),
1594 (C = O stretching). 1H NMR (CDCl3, dH): 8.36 (1H, s,
NH), 7.77–7.92 (4H, m, ArH), 5.34 (2H, m, CH=CH), 2.41
(2H, t, J= 7.40 HZ, CH2CO), 2.22 (4H, m,
CH2CH= CHCH2), 1.70 (2H, m, CH2CH2CO), 1.29 (20H,
br.s, (CH2)10), 0.87 (3H, dist.t, CH3).
13C NMR (CDCl3, dC):
174.8, 170.1, 167.2, 138.1, 134.9, 133.5, 131.9, 128.1, 127.7,
118.4, 115.6, 36.6, 34.2, 31.5, 31.2, 30.5, ‘‘two signals hidden’’,
29.5, 29.2, 29.0, 28.7, 27.5, 26.2, 24.1, 14.1. MS (ESI) m/
z= 449.500 found [M+Na]+, calculated
[M+Na]+ = 449.510.
3.1.1.8. 2-[(90Z, 120R)-120-Hydroxy octadec-90-enoyl]-3H-1,4-
phthlazindione (3d). 3392 (O-H stretching), 3227 (N-H stretch-
ing), 2921 (C–H stretching), 1585 (C = O stretching). 1H
NMR (CDCl3, dH): 8.41 (1H, s, NH), 7.34–7.67 (4H, m,
ArH), 5.50 (2H, m, CH=CH), 4.21 (1H, m, CHOH), 2.54
(2H, t, J= 7.79 HZ, CH2CO), 2.19 (1H, m, CHOH), 1.80
(4H, m, CH2CH= CHCH2), 1.65 (2H, m, CH2CH2CO),
1.27 (18H, br.s, (CH2)9), 0.88 (3H, dist.t, CH3).
13C NMR
(CDCl3, dC): 173.1, 168.8, 163.9, 134.9, 133.4, 132.7, 130.1,
126.7, 123.4, 118.8, 114.7, 72.0, 38.1, 38.0, 37.2, 36.7, 35.1,
33.9, ‘‘one signal hidden’’, 32.1, 29.4, 28.5, 27.6, 24.8, 23.1,
13.9. MS (ESI) m/z= 465.490 found [M+Na]+, calculated
[M+Na]+ = 465.513.
3.1.1.9. 2-[(90R, 120Z)-90-Hydroxy octadec-120-enoyl]-3H-1,4-
phthalazindione (3e). 3372 (O–H stretching), 3217 (N–H
stretching), 2918 (C–H stretching), 1591 (C = O stretching).
1H NMR (CDCl3, dH): 8.42 (1H, s, NH), 7.29–7.57 (4H, m,
296 A. Ahmad et al.ArH), 5.480 (2H, m, CH=CH), 4.29 (1H, m, CHOH), 2.34
(2H, t, J= 7.59 HZ, CH2CO), 2.20 (1H, m, CHOH), 1.81
(4H, m, CH2CH= CHCH2), 1.71 (2H, m, CH2CH2CO),
1.25 (18H, br.s, (CH2)9), 0.81 (3H, dist.t, CH3).
13C NMR
(CDCl3, dC): 174.5, 169.1, 162.6, 134.0, 133.9, 132.5, 131.5,
125.7, 124.4, 119.0, 112.9, 71.0, 38.9, 38.1, 37.6, 36.7, 35.8,
33.0, ‘‘one signal hidden’’, 32.1, 30.0, 29.5, 28.4, 26.4, 24.9,
14.4. MS (ESI) m/z= 465.600 found [M+Na]+, calculated
[M+Na]+ = 465.513.
3.2. Biology
All the newly synthesized compounds were assessed for in vitro
antibacterial activity against an assortment of two Gram-posi-
tive bacteria, Staphylococcus aureus SA 22, Bacillus subtilis
MTCC 121, and two Gram-negative bacteria, Escherichia coli
K12, Pseudomonas aeruginosa. Doxycycline was used as the0
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Figure 2 (A–E): Graphic representation of the antimicrobial screeni
various microbial strains. Fig. 2(A–D) shows the antibacterial activity a
Pseudomonas aeruginosa, respectively, standard used was Doxycycline
standard used was Nystatin.standard drug for the comparison of the antibacterial activity
results. The in vitro antimicrobial screening results are given in
Table 2. Graphic representation of the biological screening re-
sults is depicted in Fig. 2(A–E) in terms of diameter of zone
inhibition (in mm). The newly synthesized compounds 2(a–e)
and 3(b–e) have exerted signiﬁcant inhibitory activity against
the growth of the tested bacterial strains. The antibacterial
screening results showed that among the tested bacterial
strains, good inhibitory results were obtained against E. coli
and P. aeruginosa as depicted in Fig. 2(C) and (D). Among
the tested compounds, 3d and 3e showed more potent inhibi-
tory activity against both types of bacteria. However, depend-
ing on the nature of the heterocyclic moiety (phthalazindione/
pyrazolone) and substituents (long alkanoyl/alkenoyl/hydroxy
alkenoyl chains) attached to it exerted varying inhibitory ac-
tions. In another set of experiments, all the newly synthesized
compounds 2(a–e) and 3(b–e) were also screened for in vitro
antifungal activity against C. albicans IOA 109. Nystatin was0
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ng results in terms of diameter of inhibition zone (in mm) against
gainst Bacillus subtilis, Staphylococcus aureus, Escherichia coli and
. Fig. 2(E) shows the antifungal activity against Candida albicans,
Table 2 In vitro antimicrobial screening data of compounds 2(a–e) and 3(b–e).
Test
sample
Concentration
(lg/mL)
Bacillus
subtilis
Staphylococcus
aureus
Escherichia
coli
Pseudomonas
aeruginosa
Candida
albicans
2a 400 – – 10 11 –
800 – – 14 17 13
2b 400 – – 14 16 11
800 15 14 22 19 16
2c 400 – – 13 13 10
800 – – 17 19 14
2d 400 11 10 15 15 14
800 13 13 22 21 18
2e 400 10 11 13 13 13
800 13 14 19 20 17
3b 400 – – 14 13 11
800 11 13 20 16 17
3c 400 – – 14 – 10
800 – – 19 14 15
3d 400 13 11 18 14 13
800 17 15 22 24 19
3e 400 11 11 15 15 14
800 16 15 23 22 20
Doxycycline 30 (lg/disc) 20 18 23 21
NA
Nystatin 30 (lg/disc) NA NA NA NA 18
*NA: Not applicable.
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results. The synthesized compounds showed moderate to excel-
lent inhibitory results for C. albicans as seen in Fig. 2(E).
3.2.1. Structure–activity relationship (SAR) studies
The structure–activity studies showed that depending on the
nature of the heterocyclic skeleton and its substituent, the new-
ly synthesized compounds 2(a–e) and 3(b–e) exhibit varying
degree of microbial inhibition. From the antimicrobial screen-
ing results, it has been found that the phthalazindione deriva-
tives 3(b–e) have shown better activity as compared to their
corresponding pyrazolone derivatives 2(a–e). Within the same
heterocyclic series that is either in phthalazindione derivatives
or in pyrazolone derivatives, the inhibitory activity depends on
the nature of substituents attached to them. The in vitro bio-
logical screening indicated that the presence of the hydroxy
substituents attached to the heterocyclic moiety as in com-
pounds (2d, 2e, 3d and 3e) increased their inhibitory activities
compared to other compounds. Structure activity relationship
(SAR) studies cleared that, compounds with terminal alkenoyl
substituent (2b and 3b) and smaller carbon chain (C10) have
better inhibitory activity compared with compounds (2c and
3c) which have internal alkenoyl substituent and longer carbon
chain (C17). Further, SAR studies show that heterocyclic moi-
ety having alkanoyl substituent (2a) which is analogue of sat-
urated fatty acid and having long carbon atom chain (C15)
shows very small inhibitory results. The values of diameter
of zone of inhibition in mm for all the newly synthesized com-
pounds are pictorially represented in graphical form in
Fig. 2(A–E) against B. subtilis, S. aureus, E. coli, Pseudomonas
aeruginosa and C. albicans, respectively. The maximum inhibi-
tion was observed in phthalazindione derivatives substitutedwith hydroxy substituent i.e., 3d and 3e against P. aeruginosa
with zone diameter of 14 and 15 mm, respectively (at 400 lg/
mL concentration) and also with zone diameter of 24 and
22 mm, respectively (at 800 lg/mL concentration) as seen in
Fig. 2(D). The compounds 3d and 3e also show good inhibi-
tory activity against E. coli with zone diameter of 18 and
15 mm, respectively (at 400 lg/mL concentration) and with
zone diameter of 22 and 23 mm, respectively (at 800 lg/mL
concentartion) as depicted in Fig. 2(C). Hence, we summarized
that higher activity of compounds 2d, 2e, 3d and 3e may be
attributed to the presence of hydroxy substituents. Also, the
synthesized compounds with phthalazindione rings substituted
with hydroxy group (3d and 3e) show excellent activity as com-
pared to pyrazolone rings substituted with hydroxy group (2d
and 2e). Thus, the nature of substituents and the heterocyclic
skeleton of molecules have a strong inﬂuence on the extent
of antibacterial and antifungal activities.
4. Conclusion
To the best of our knowledge these alkanoyl/alkenoyl/hydrox-
yalkenoyl pyrazolone and phthalazindione derivatives of some
selected fatty acids have been synthesized for the ﬁrst time. The
salient features of these procedures includes mild reaction con-
ditions, use of inexpensive reagents and starting material,
products were obtained in good to excellent yields. The struc-
ture–activity studies showed that depending on the nature of
heterocyclic skeleton and its substituent, the newly synthesized
compounds 2(a–e) and 3(b–e) exhibit varying degree of micro-
bial inhibition. The in vitro biological screening results show
that compounds having hydroxy substituent attached to the
heterocyclic moiety (2d, 2e, 3d and 3e) were the most promis-
298 A. Ahmad et al.ing antimicrobial agents. The maximum inhibition was ob-
served in phthalazindione derivatives substituted with hydroxy
substituent i.e., 3d and 3e. The synthesis will be a valuable
addition to the synthetic methodology available for the synthe-
sis of heterocyclic derivatives of fatty acids which are useful
biologically as well as industrially. From these studies it is
understandable that further derivatization and heterocycliza-
tion of these hetero-analogues of fatty acids can be served as
new templates for antimicrobial drug discovery and could
probably lead to more potent agents in this ﬁeld.Acknowledgments
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